Janus Kinase Inhibitors for Alopecia Areata

作者：Ming Liu, Ya Gao, Yuan Yuan, Kelu Yang, Caiyi Shen, Jiancheng Wang, Jinhui Tian · 发表于：JAMA Network Open · 年份：2023 · DOI：10.1001/jamanetworkopen.2023.20351 · 被引用次数：56 · 研究领域：Hair Growth and Disorders、Dermatology and Skin Diseases、Cytokine Signaling Pathways and Interactions

Importance: Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease. Several studies have reported outcomes of Janus kinase (JAK) inhibitors for treating AA, but limited evidence has emerged. Objective: To evaluate the effectiveness and safety associated with JAK inhibitors for AA. Data Sources: MEDLINE, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) were searched from inception until August 2022. Study Selection: Only randomized clinical trials (RCTs) were included. Pairs of reviewers independently and in duplicate selected the studies. Data Extraction and Synthesis: Hartung-Knapp-Sidik-Jonkman random-effects models were used for meta-analysis. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Main Outcomes and Measures: The primary outcomes of interest were (1) proportion of patients who achieved 30%, 50%, and 90% improvement in Severity of Alopecia Tool (SALT) score from baseline, (2) change from baseline SALT score, and (3) treatment-related adverse event (AE). Results: Seven RCTs with 1710 patients (1083 females [63.3%]; mean [SD] age range, 36.3 [10.4] to 69.7 [16.2] years) were eligible and included in the study. JAK inhibitors were associated with more patients achieving 50% improvement (odds ratio [OR], 5.28 [...